Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs
BMC Pharmacology March 3, 2006 DOI: 10.1186/1471-2210-6-6 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | In vitro laboratory study Peer reviewed |
|---|---|
| Population | Human and mouse dopamine, norepinephrine, and serotonin transporters expressed in cells |
| Interventions | Cocaine methylphenidate amphetamine methamphetamine MDMA |
| Topics | MDMA Serotonin |
| Keywords | Monoamine neurotransmitter Pharmacology Dopamine transporter Norepinephrine transporter Methamphetamine Reuptake inhibitor Methylphenidate Serotonin transporter |
| Citations | 419 |
| Key points | Cocaine blocks all three monoamine transporters at similar concentrations, whereas methylphenidate, amphetamine, methamphetamine, and MDMA show distinct selectivity profiles among DAT, NET, and SERT. |
Abstract
Abstract Background The plasma membrane neurotransmitter transporters terminate neurotransmissions by the reuptake of the released neurotransmitters. The transporters for the monoamines dopamine, norepinephrine, and serotonin (DAT, NET, and SERT) are targets for several popular psychostimulant drugs of abuse. The potencies of the psychostimulant on the monoamine transporters have been studied by several laboratories. However, there are significant discrepancies in the reported data with differences up to 60-fold. In addition, the drug potencies of the 3 monoamine transporters from mouse have not been compared in the same experiments or along side the human transporters. Further studies and systematic comparisons are needed.
Results: In this study, we compared the potencies of five psychostimulant drugs to inhibit human and mouse DAT, SERT and NET in the same cellular background. The K I values of cocaine to inhibit the 3 transporters are within a narrow range of 0.2 to 0.7 μM. In comparison, methylphenidate inhibited DAT and NET at around 0.1 μM, while it inhibited SERT at around 100 μM. The order of amphetamine potencies was NET (K I = 0.07–0.1 μM), DAT (K I ≈ 0.6 μM), and SERT (K I between 20 to 40 μM). The results for methamphetamine were similar to those for amphetamine. In contrast, another amphetamine derivative, MDMA (3–4 methylenedioxymethamphetamine), exhibited higher potency at SERT than at DAT. The human and mouse transporters were similar in their sensitivities to each of the tested drugs (K I values are within 4-fold).
Conclusion: The current and previous studies support the following
Conclusions: 1) cocaine blocks all 3 monoamine transporters at similar concentrations; 2) methylphenidate inhibits DAT and NET well but a 1000-fold higher concentration of the drug is required to inhibit SERT; 3) Amphetamine and methamphetamine are most potent at NET, while being 5- to 9-fold less potent at DAT, and 200- to 500-fold less potent at SERT; 4) MDMA has moderately higher apparent affinity for SERT and NET than for DAT. The relative potencies of a drug to inhibit DAT, NET and SERT suggest which neurotransmitter systems are disrupted the most by each of these stimulants and thus the likely primary mechanism of drug action.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
State of the evidence: MDMA Supports
MDMA was more potent at the serotonin transporter than at the dopamine transporter, unlike amphetamine and methamphetamine.
Synthesized
Comparable studies
Other preclinical and animal studies on MDMA, most cited first.
Citations in the library
Cited by 53
- Duloxetine Inhibits Effects of MDMA (“Ecstasy") In Vitro and in Humans in a Randomized Placebo-Controlled Laboratory Study PLoS One May 4, 2012
- The Norepinephrine Transporter Inhibitor Reboxetine Reduces Stimulant Effects of MDMA (“Ecstasy”) in Humans Clinical Pharmacology & Therapeutics June 15, 2011
- Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination The International Journal of Neuropsychopharmacology October 8, 2013
- Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects Psychopharmacology May 27, 2017
- Pharmacological profile of novel psychoactive benzofurans British Journal of Pharmacology March 13, 2015
and 48 more in the library